Skip to main content
Premium Trial:

Request an Annual Quote

Stephen Hurly, Mark Schoenebaum, Robyn Karnauskas, Greg Tronto, David Girling, Lorraine Keller, Maureen O’Leary

Boenning and Scattergood Taps Leader for Investment Banking Effort in Biotech, Pharma
Stephen Hurly has joined the investment banking group of Boenning and Scattergood, an independent securities, asset management, and investment banking firm headquartered in
Hurly has been named a managing director, focusing on publicly traded companies and privately held businesses in the healthcare, biotechnology and pharmaceutical sectors. He will work out of the firm’s offices in the Philadelphia suburb of West Conshohocken, Pa., as well as New York City.
Hurly previously served as managing director and head of the health care group at Janney Montgomery Scott. Prior to 2004, Hurly worked in San Francisco for Hambrecht and Quist, and JP Morgan, and in New York City for Wasserstein Perella.
Hurly earned a BSci in engineering from Swarthmore College and an MBA from the University of Chicago.

Two Bear Stearns Veterans With Healthcare/Biotech Focus Join Deutsche Bank Securities
Mark Schoenebaum has been named a managing director and senior research analyst in equity company research within the global markets division of Deutsche Bank Securities. He will be based in New York.
Schoenebaum previously worked for Bear Stearns as a senior managing director covering biotechnology in equity research. He has spent the past eight years as an equity research analyst, the last three of which he was ranked number-one in the Institutional Investor All-America Research poll for biotechnology.
Before joining Bear Stearns, Schoenebaum was co-director of healthcare equity research at Alexandra Investment Management, and previously spent two years as an analyst at Piper Jaffray. Schoenebaum earned a BA from Indiana University and an MD from Johns Hopkins University School of Medicine.
Deutsche Bank Securities also announced that Robyn Karnauskas has joined the firm as a vice president and research analyst in equity company research.
Karnauskas was previously an associate director at Bear Stearns covering biotechnology. She is based in New York and reports to Schoenebaum.
Karnauskas earned a BSci in biology from the Massachusetts Institute of Technology and a PhD in cancer biology from the University of Chicago.

Greg Tronto Named to Board of Directors of Delaware BioScience Association
Greg Tronto, business leader for single-use bioprocess components at the Gore PharmBIO Products unit of medical device maker WL Gore and Associates, has been named to the Delaware BioScience Association board of directors. Established in 2006, the association is a non-profit trade group that works to advance the bioscience industry in Delaware and the Mid-Atlantic region.
Tronto joined WL Gore in 1988. Before taking on his current position last year, Tronto advanced from a product specialist for industrial pleated cartridge filters used for high-temperature process applications in minerals, metals and chemicals; to leader of Gore’s industrial EPTFe cleanable filtration media business, whose global operations he launched, developed and established; to a new business development position.
He is listed as a co-inventor on US filter patent 5,207,812, issued in 1995.
Tronto has a BSci degree in mechanical engineering from Widener University in Chester, Pa. A resident of Hockessin, Del., Tronto is married with two children.

Financial Services, Capital Markets Veteran Joins No World Borders Advisory Board
David Girling has joined the advisory board of No World Borders, a global provider of management and IT consulting services to clients that include healthcare, retail, medical device, pharmaceutical, biotechnology, and other high-tech businesses.
Girling most recently served as president and CEO of LogicEase Solutions, a provider of compliance and risk management solutions for the financial services industry.
Previously, he held executive positions at First Boston (now Credit Suisse), Shearson Lehman Mortgage, and GE Capital. He also worked with a number of start-up companies including Ellie Mae, Sigma Designs, and LogicEase.
Girling also served as a vice president with PricewaterhouseCoopers’ emerging company practice, where he consulted with start-up and venture capital firms in San Francisco. Girling also worked for First Republic in its private banking and wealth advisory group.
Girling received an MBA from the Anderson Graduate School of Management at the University of California at Los Angeles, and graduated from the University of Southern California with a BBA.

Virtual Incubator for Greater Philadelphia Life Sciences Companies Adds Portfolio Manager, Program Director
BioStrategy Partners, a virtual incubator that offers technology and business development services to emerging-stage life science companies in the greater Philadelphia area, has added two professionals with experience in technology commercialization.
Lorraine Keller has been named portfolio manager for the virtual incubator’s corporate development program, while Maureen O’Leary has been named program director for the organization’s due diligence program respectively.
Keller serves as key contact for the companies in BioStrategy Partners’ corporate development program, which assists companies in fulfilling customized milestones. The program links companies to mentors, experts and providers of services that include marketing, business strategy, financial planning, intellectual property assessment, licensing, regulatory affairs, and human resources. Four companies are currently in the corporate development program.

Keller was co-founder and executive vice president of the biotech company Immunotope, a developer of immunotherapies to treat and prevent cancer and infectious diseases. She was a co-founder and vice president of marketing and communication for RheoGene, and a founding member of the scientific advisory board of BioStrategy Partners. She earlier worked at Rohm and Haas as a senior scientist in the biotechnology group, and as a program manager in human and environmental toxicology.

Keller holds a BA degree in biological sciences from Smith College, and received a PhD in plant physiology and molecular biology from Cornell University.

O’Leary meets with company executives during their application process to BioStrategy Partners, and is responsible for leading these emerging firms through the organization’s due diligence program, which includes planning and start-up assistance, introductions and networking opportunities, and in-depth business and technical reviews by a panel tailored for each company. The review determines a company’s eligibility for BioSP’s corporate development program, which since August 2007 has seen participation from about 10 companies.

O’Leary helped launch 15 startup companies as director of start-up business development at the University of Pennsylvania’s Center for Technology Transfer. During her 10-year career, O’Leary has had primary responsibility for over 200 technology transfer agreements.

O’Leary holds a BA from Wellesley College and a PhD in physics from the University of Pennsylvania.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.